Clinical trials: Nutritional Deficiencies
Amyotrophic Lateral Sclerosis
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
- Trial name
- NCT04066244
- Testing
- BLZ945
- Where
- 4 sites in United States, Finland and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency Anaemia
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
The purpose of the trial is to evaluate and compare the effect of iron isomaltoside 1000 to iron sucrose in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be…
- Trial name
- Provide (NCT02130063)
- Testing
- iron isomaltoside 1000 (Monofer®), iron sucrose (Venofer®)
- Where
- United States
- Volunteers
- 511 people
- Sponsor
- Pharmacosmos A/S
Amyotrophic Lateral Sclerosis (ALS)
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy
- Trial name
- ALS (NCT03580616)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Elijah W. Stommel
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
This study is designed to evaluate the safety, reactogenicity, and immunogenicity of Na-GST-1 adsorbed to Alhydrogel® with or without two different dose concentrations of a novel adjuvant, GLA-AF (1 µg or 5 μg) among healthy…
- Trial name
- NCT01385189
- Testing
- 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Phosphorus and Calcium Disorders, Chronic Kidney Disease Mineral and Bone Disorder
Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
This pilot study aims to develop a method for simultaneous whole-body calcium and phosphorus balance and full kinetic modeling of both ions in patients with chronic kidney disease.
- Conditions
- Phosphorus and Calcium Disorders, Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Diseases
- Trial name
- NCT04019379
- Testing
- High Phosphorus Diet, Low Phosphorus Diet
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Minnesota
TTR-mediated Amyloidosis, Amyloidosis, Hereditary
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis.
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies
- Trial name
- NCT01960348
- Testing
- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
- Where
- 52 sites in United States, Argentina and 19 more
- Volunteers
- 225 people
- Sponsor
- Alnylam Pharmaceuticals
Amyotrophic Lateral Sclerosis
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.
- Trial name
- NCT03836716
- Testing
- Arimoclomol
- Where
- 23 sites in United States, Belgium and 9 more
- Volunteers
- 120 people
- Sponsor
- ZevraDenmark
Amyotrophic Lateral Sclerosis
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral…
- Trial name
- NCT01906658
- Testing
- Repository corticotropin injection
- Where
- 17 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mallinckrodt
Heart Transplant Recipients
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Iron deficiency is prevalent in heart transplant recipients, and may be associated with reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous iron isomaltoside on exercise capacity, muscle…
- Trial name
- IronIC (NCT03662789)
- Testing
- Iron Isomaltoside 1000
- Where
- Norway
- Volunteers
- 102 people
- Sponsor
- Oslo University Hospital
Multiple Myeloma, Amyloidosis
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage…
- Trial name
- NCT02158052
- Testing
- Tacrolimus, Equine Anti-thymocyte globulin, Kidney transplant from a related donor
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Light-Chain Amyloidosis
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated…
- Trial name
- NCT01318902
- Testing
- Ixazomib, Dexamethasone
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Craniocerebral Trauma, Intracranial Aneurysm
Hypovitaminosis D in Neurocritical Patients
Vitamin D has been shown to impact prognosis in a variety of retrospective and randomized clinical trials within an intensive care unit (ICU) environment.
- Conditions
- Craniocerebral Trauma, Intracranial Aneurysm, Brain Neoplasms, Spinal Cord Injuries
- Trial name
- NCT02881957
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- University of Utah
Ovarian Cancer, Breast Cancer
A Study of Serum Folate Levels in Patients Treated With Olaparib
This is a study investigating folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib to treat their advanced ovarian or breast cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Folic Acid Deficiency
- Trial name
- NCT04024254
- Testing
- Folic Acid Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis.
- Trial name
- NCT01078454
- Testing
- melphalan, dexamethasone, bortezomib
- Where
- 209 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Amyotrophic Lateral Sclerosis (ALS)
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores…
- Trial name
- NCT01492686
- Testing
- MCI-186, MCI-186 in open label phase
- Where
- Japan
- Volunteers
- 137 people
- Sponsor
- Shionogi
Amyloid Cardiomyopathy
Open-Label Study of AG10 in Patients With Cardiomyopathy
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
- Trial name
- NCT03536767
- Testing
- Acoramidis
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto
Amyotrophic Lateral Sclerosis
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
This is a multi-center, 20-week study of inosine treatment. Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily)…
- Trial name
- SURE-ALS2 (NCT03168711)
- Testing
- Inosine
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Non-anemic Iron Deficiency
Iron Treatment for Young Children With Non-anemic Iron Deficiency
The pre-school years are critical years for children to acquire early learning skills such as language, fine motor and social skills; this is termed early child development.
- Trial name
- OptEC (NCT01481766)
- Testing
- Ferrous Sulfate, Dietary counseling
- Where
- 2 sites in Canada
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Amyotrophic Lateral Sclerosis, ALS
Clinical Trial Ceftriaxone in Subjects With ALS
The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00349622
- Testing
- ceftriaxone
- Where
- 58 sites in United States, Canada
- Volunteers
- 513 people
- Sponsor
- Massachusetts General Hospital